期刊
STEM CELL REPORTS
卷 9, 期 1, 页码 1-4出版社
CELL PRESS
DOI: 10.1016/j.stemcr.2017.05.029
关键词
-
资金
- The International Stem Cell Forum
- UK Regenerative Medicine Platform [MR/L012537/1]
- Ajinomoto Inc.
- Stem Cell Technologies Inc.
- International Stem Cell Forum
- Thermo Fisher Scientific
- Biotechnology and Biological Sciences Research Council [BBS/E/B/000C0421, BBS/E/B/000C0402, BBS/E/B/000C0422] Funding Source: researchfish
- Medical Research Council [MC_qA137863, MR/L022842/1, MR/L012537/1, MC_qA137916] Funding Source: researchfish
- BBSRC [BBS/E/B/000C0402, BBS/E/B/000C0422, BBS/E/B/000C0421] Funding Source: UKRI
- MRC [MR/L012537/1, MR/L022842/1, MC_qA137916] Funding Source: UKRI
Pluripotent stem cells may acquire genetic and epigenetic variants during culture following their derivation. At a conference organized by the International Stem Cell Initiative, and held at The Jackson Laboratory, Bar Harbor, Maine, October 2016, participants discussed how the appearance of such variants can be monitored and minimized and, crucially, how their significance for the safety of therapeutic applications of these cells can be assessed. A strong recommendation from the meeting was that an international advisory group should be set up to review the genetic and epigenetic changes observed in human pluripotent stem cell lines and establish a framework for evaluating the risks that they may pose for clinical use.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据